Appointment of M/s. Shah & Shah Associates, Chartered Accountants as Internal Auditor of the Company for the F.Y. 2026-27
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Corona Remedies Ltd reported strong FY 2025-26 results with standalone revenue of Rs 1,403.18 crore (up 17% from Rs 1,196.42 crore) and net profit of Rs 184.85 crore (up 24% from Rs 149.05 crore). EPS grew to Rs 30.22 from Rs 24.37. The Board recommended a final dividend of Rs 10 per share (100% payout) with record date June 19, 2026. Key auditor changes include appointment of M/s. Walker Chandiok & Co LLP as new statutory auditor for 5 years (replacing Deloitte Haskins & Sells LLP) and M/s. Shah & Shah Associates as internal auditor for FY 2026-27. Dr. Kirtikumar Mehta is re-appointed as Non-Executive Chairman for 5 years from April 1, 2027. The company listed on NSE and BSE in December 2025 via an IPO. Total assets grew to Rs 1,204.25 crore from Rs 929.24 crore.
Strong financial growth with 24% profit increase and maiden dividend post-IPO signals healthy operational performance. Leadership changes in statutory and internal audit roles may bring fresh perspective to governance, while chairman re-appointment provides stability.